Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
THOR's Cash to Debt is ranked higher than
87% of the 509 Companies
in the Global Medical Devices industry.

( Industry Median: 2.15 vs. THOR: No Debt )
THOR' s 10-Year Cash to Debt Range
Min: 0.94   Max: No Debt
Current: No Debt

Equity to Asset 0.83
THOR's Equity to Asset is ranked higher than
88% of the 472 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. THOR: 0.83 )
THOR' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.88
Current: 0.83

0.39
0.88
Interest Coverage 2914.08
THOR's Interest Coverage is ranked higher than
67% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 365.56 vs. THOR: 2914.08 )
THOR' s 10-Year Interest Coverage Range
Min: 2.02   Max: 9999.99
Current: 2914.08

2.02
9999.99
F-Score: 5
Z-Score: 12.27
M-Score: -2.73
WACC vs ROIC
5.43%
14.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 14.64
THOR's Operating margin (%) is ranked higher than
89% of the 485 Companies
in the Global Medical Devices industry.

( Industry Median: 4.94 vs. THOR: 14.64 )
THOR' s 10-Year Operating margin (%) Range
Min: -82.51   Max: 27.01
Current: 14.64

-82.51
27.01
Net-margin (%) 10.55
THOR's Net-margin (%) is ranked higher than
88% of the 485 Companies
in the Global Medical Devices industry.

( Industry Median: 2.98 vs. THOR: 10.55 )
THOR' s 10-Year Net-margin (%) Range
Min: -77.49   Max: 16.92
Current: 10.55

-77.49
16.92
ROE (%) 7.63
THOR's ROE (%) is ranked higher than
78% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. THOR: 7.63 )
THOR' s 10-Year ROE (%) Range
Min: -36.67   Max: 45.42
Current: 7.63

-36.67
45.42
ROA (%) 6.41
THOR's ROA (%) is ranked higher than
85% of the 512 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. THOR: 6.41 )
THOR' s 10-Year ROA (%) Range
Min: -25   Max: 38.18
Current: 6.41

-25
38.18
ROC (Joel Greenblatt) (%) 47.53
THOR's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 509 Companies
in the Global Medical Devices industry.

( Industry Median: 5.54 vs. THOR: 47.53 )
THOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -198.59   Max: 83.88
Current: 47.53

-198.59
83.88
Revenue Growth (3Y)(%) 7.60
THOR's Revenue Growth (3Y)(%) is ranked higher than
81% of the 342 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. THOR: 7.60 )
THOR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.1   Max: 71.9
Current: 7.6

-2.1
71.9
EBITDA Growth (3Y)(%) -11.60
THOR's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. THOR: -11.60 )
THOR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -11.6   Max: 133.5
Current: -11.6

-11.6
133.5
EPS Growth (3Y)(%) -9.50
THOR's EPS Growth (3Y)(%) is ranked higher than
71% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. THOR: -9.50 )
THOR' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.2   Max: 196.2
Current: -9.5

-66.2
196.2
» THOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

THOR Guru Trades in Q2 2014

Joel Greenblatt 402,924 sh (New)
Paul Tudor Jones 18,138 sh (+39.24%)
Manning & Napier Advisors, Inc 661,190 sh (+19.90%)
Chuck Royce 622,900 sh (unchged)
Jim Simons 923,939 sh (-12.09%)
» More
Q3 2014

THOR Guru Trades in Q3 2014

Joel Greenblatt 970,893 sh (+140.96%)
Manning & Napier Advisors, Inc 1,575,340 sh (+138.26%)
Paul Tudor Jones 33,802 sh (+86.36%)
Chuck Royce 348,300 sh (-44.08%)
Jim Simons 132,939 sh (-85.61%)
» More
Q4 2014

THOR Guru Trades in Q4 2014

Manning & Napier Advisors, Inc 1,857,440 sh (+17.91%)
Chuck Royce Sold Out
Jim Simons Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2015

THOR Guru Trades in Q1 2015

Manning & Napier Advisors, Inc 1,219,930 sh (-34.32%)
» More
» Details

Insider Trades

Latest Guru Trades with THOR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 48.00
THOR's P/E(ttm) is ranked higher than
78% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 48.00 )
THOR' s 10-Year P/E(ttm) Range
Min: 19.97   Max: 541.28
Current: 48

19.97
541.28
Forward P/E 28.90
THOR's Forward P/E is ranked higher than
87% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 28.90 )
N/A
PE(NRI) 49.80
THOR's PE(NRI) is ranked higher than
82% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 49.80 )
THOR' s 10-Year PE(NRI) Range
Min: 20.06   Max: 527.75
Current: 49.8

20.06
527.75
P/B 3.80
THOR's P/B is ranked higher than
65% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. THOR: 3.80 )
THOR' s 10-Year P/B Range
Min: 1.42   Max: 4.72
Current: 3.8

1.42
4.72
P/S 5.02
THOR's P/S is ranked higher than
57% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 4.30 vs. THOR: 5.02 )
THOR' s 10-Year P/S Range
Min: 2.7   Max: 8.2
Current: 5.02

2.7
8.2
PFCF 29.20
THOR's PFCF is ranked higher than
85% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 29.20 )
THOR' s 10-Year PFCF Range
Min: 12.79   Max: 2111
Current: 29.2

12.79
2111
POCF 27.22
THOR's POCF is ranked higher than
83% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 27.22 )
THOR' s 10-Year POCF Range
Min: 11.81   Max: 175.92
Current: 27.22

11.81
175.92
EV-to-EBIT 30.36
THOR's EV-to-EBIT is ranked higher than
83% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 30.36 )
THOR' s 10-Year EV-to-EBIT Range
Min: -3731.1   Max: 287.2
Current: 30.36

-3731.1
287.2
PEG 33.20
THOR's PEG is ranked higher than
91% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 33.20 )
THOR' s 10-Year PEG Range
Min: 0.54   Max: 512.38
Current: 33.2

0.54
512.38
Shiller P/E 43.60
THOR's Shiller P/E is ranked higher than
85% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 43.60 )
THOR' s 10-Year Shiller P/E Range
Min: 23.74   Max: 427.2
Current: 43.6

23.74
427.2
Current Ratio 4.96
THOR's Current Ratio is ranked higher than
84% of the 508 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. THOR: 4.96 )
THOR' s 10-Year Current Ratio Range
Min: 3.16   Max: 11.27
Current: 4.96

3.16
11.27
Quick Ratio 4.20
THOR's Quick Ratio is ranked higher than
84% of the 508 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. THOR: 4.20 )
THOR' s 10-Year Quick Ratio Range
Min: 2.03   Max: 9.4
Current: 4.2

2.03
9.4
Days Inventory 145.06
THOR's Days Inventory is ranked higher than
74% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 173.97 vs. THOR: 145.06 )
THOR' s 10-Year Days Inventory Range
Min: 65.17   Max: 330.47
Current: 145.06

65.17
330.47
Days Sales Outstanding 55.68
THOR's Days Sales Outstanding is ranked higher than
85% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 84.35 vs. THOR: 55.68 )
THOR' s 10-Year Days Sales Outstanding Range
Min: 25.54   Max: 91.69
Current: 55.68

25.54
91.69

Valuation & Return

vs
industry
vs
history
Price/Net Cash 23.40
THOR's Price/Net Cash is ranked higher than
82% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 23.40 )
THOR' s 10-Year Price/Net Cash Range
Min: 4.25   Max: 363.8
Current: 23.4

4.25
363.8
Price/Net Current Asset Value 12.60
THOR's Price/Net Current Asset Value is ranked higher than
78% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 12.60 )
THOR' s 10-Year Price/Net Current Asset Value Range
Min: 2.61   Max: 196.88
Current: 12.6

2.61
196.88
Price/Tangible Book 6.40
THOR's Price/Tangible Book is ranked higher than
66% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 8.40 vs. THOR: 6.40 )
THOR' s 10-Year Price/Tangible Book Range
Min: 2.33   Max: 143.18
Current: 6.4

2.33
143.18
Price/DCF (Projected) 1.60
THOR's Price/DCF (Projected) is ranked higher than
93% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 1.60 )
THOR' s 10-Year Price/DCF (Projected) Range
Min: 1.19   Max: 7.75
Current: 1.6

1.19
7.75
Price/Median PS Value 1.10
THOR's Price/Median PS Value is ranked higher than
75% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. THOR: 1.10 )
THOR' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 14.72
Current: 1.1

0.69
14.72
Price/Graham Number 3.60
THOR's Price/Graham Number is ranked higher than
82% of the 578 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. THOR: 3.60 )
THOR' s 10-Year Price/Graham Number Range
Min: 1.87   Max: 10.04
Current: 3.6

1.87
10.04
Earnings Yield (Greenblatt) 3.30
THOR's Earnings Yield (Greenblatt) is ranked higher than
78% of the 495 Companies
in the Global Medical Devices industry.

( Industry Median: 1.30 vs. THOR: 3.30 )
THOR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 9.8
Current: 3.3

0.3
9.8
Forward Rate of Return (Yacktman) 1.19
THOR's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 212 Companies
in the Global Medical Devices industry.

( Industry Median: 3.98 vs. THOR: 1.19 )
THOR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.2   Max: 45.7
Current: 1.19

-7.2
45.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:TL1.Germany,
Thoratec Corporation incorporated in the State of California in 1976 provides mechanical circulatory support with a product portfolio to treat the full range of clinical needs for advanced heart failure patients. It develops, manufactures and markets proprietary medical devices used for circulatory support. Following the sale of ITC in 2010, the Company has one operating segment: Cardiovascular group. This segment is organized and operates to develop and manufacture mechanical circulatory products to support the cardiovascular systems of humans. The Company's VAD products primarily serve patients suffering from late-stage HF. HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. Hospitals that perform open heart surgery and heart transplants are the potential customers for its Thoratec and HeartMate products. The Company estimates that it sells into 293 of these centers. According to the Company's estimates, it is in approximately 149 centers in the United States and 144 centers internationally. Competition from medical device companies and medical device divisions of healthcare companies, pharmaceutical companies and gene- and cell-based therapies is intense and is expected to increase. It therefore continues to expect new competitors both from the pharmacological and the medical device space. Among the medical device competitors are Aachen Innovative Solutions GmbH, AbioMed, Inc., Berlin Heart GmbH, HeartWare International Inc., Jarvik Heart, Inc., Maquet Cardiovascular, LLC (a division of Getinge AB), MicroMed Technology, Inc., Sun Medical Technology Research Corporation, SynCardia Systems, Inc., and Terumo Heart, Inc. All of the Company's proposed products will require regulatory approval prior to commercialization. In particular, medical devices are subject to rigorous pre-clinical testing as a condition of approval by the FDA and by similar authorities in foreign countries.
» More Articles for THOR

Headlines

Articles On GuruFocus.com
5-year lows: Thoratec Corp, Brady Corp, General Cable Corp, and UTi Worldwide Inc. Aug 25 2014 
5-year lows: Mack-Cali Realty Corp, Thoratec Corp, Brady Corp, and EXCO Resources Inc. Aug 10 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Weekly Guru Bargains Highlights: CSTR, VRX, SAY, THOR, BVN Feb 12 2011 
Weekly Guru Bargains Highlights: CSTR, VRX, SAY, THOR, BVN Feb 12 2011 
Weekly Guru Bargains Highlights: SVU, MSI, THOR, JNY, AMLN Jan 23 2011 
Weekly Guru Bargains Highlights: DF, CLWR, THOR, VRX, ASIA Dec 26 2010 
Weekly Guru Bargains Highlights: TFSL, THOR, CISG, VRX, DLR Dec 18 2010 
Weekly Guru Bargains Highlights: THOR, SKX, AMLN, SAY, JOE Dec 12 2010 


More From Other Websites
Thoratec Schedules First Quarter Conference Call, Webcast Apr 20 2015
Thoratec Schedules First Quarter Conference Call, Webcast Apr 20 2015
Thoratec's HeartMate II Scores High in ENDURANCE Trial - Analyst Blog Apr 17 2015
ROADMAP Study Demonstrates HeartMate II® Benefits In Ambulatory Advanced Heart Failure Patients Apr 17 2015
ROADMAP Study Demonstrates HeartMate II® Benefits In Ambulatory Advanced Heart Failure Patients Apr 17 2015
ROADMAP Study Demonstrating Benefits of HeartMate II(R) Left Ventricular Assist Device Presented at... Apr 17 2015
Thoratec Hits 52-Week High on Favorable Developments - Analyst Blog Apr 16 2015
Thoratec Comments On HeartMate II® Data In ENDURANCE Destination Therapy Trial Apr 16 2015
Thoratec Comments On HeartMate II® Data In ENDURANCE Destination Therapy Trial Apr 16 2015
HeartWare Gets VAD Distribution Approval from Health Canada - Analyst Blog Apr 15 2015
Medtronic PLC (MDT), AbbVie Inc. (ABBV), Humana Inc (HUM): Rock Springs Capital Rides Healthcare... Apr 14 2015
THORATEC CORP Files SEC form 8-K, Change in Directors or Principal Officers Apr 08 2015
Thoratec Wins FDA Consent to Expand HeartMate III US Trial - Analyst Blog Apr 06 2015
Thoratec To Webcast Investor Meeting At ISHLT Conference Apr 06 2015
Thoratec To Webcast Investor Meeting At ISHLT Conference Apr 06 2015
Thoratec Receives Approval From FDA For Full Expansion Of HeartMate III™ U.S. IDE Clinical Trial Apr 02 2015
Thoratec Receives Approval From FDA For Full Expansion Of HeartMate III™ U.S. IDE Clinical Trial Apr 02 2015
How to Play the Healthcare Rally Apr 01 2015
Thoratec® Reports Fourth Quarter 2014 Results Mar 06 2015
Heartware International Posts Q4 Loss; MVAD Holds Promise - Analyst Blog Mar 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK